Literature DB >> 12548218

Protective effect of N-acetylcysteine against fetal death and preterm labor induced by maternal inflammation.

Irina A Buhimschi1, Catalin S Buhimschi, Carl P Weiner.   

Abstract

OBJECTIVE: Intrauterine and maternal systemic infections are proposed causes of preterm labor. The resulting prematurity is associated with 75% of infant mortality and 50% of long-term neurologic handicaps. We hypothesize that free radicals generated in large quantities during an inflammatory response shift the fetomaternal redox balance to an oxidative state, compromising the fetus. Thus, if our working hypothesis is correct, selective inactivation of free radicals with N-acetylcysteine (NAC), an antioxidant and glutathione (GSH) precursor, would improve the outcome of preterm deliveries associated with inflammation. We tested aspects of this hypothesis in an animal model of preterm labor and fetal damage (death). STUDY
DESIGN: NAC (1 g/kg) was administered orally to C57Bl/6 mice injected intraperitoneally with either 10 microg lipopolysaccharide (LPS) or saline solution (CRL) on day 16 of gestation. The latency period (time from injection to delivery of the first pup) and fetal viability were recorded. To discriminate between an effect of prematurity from an effect of inflammation, and to document any improvement in survival, mice were killed at 3, 6, and 16 hours after injection. Maternal and fetal redox states were approximated by measuring hepatic GSH.
RESULTS: Each C57Bl/6 LPS-treated mouse delivered prematurely after a significantly shorter latency period (LPS: 16.8 hours [95% CI 15.9-17.6] vs CRL: 54.7 hours [95% CI 43.8-65.5]). NAC doubled the latency interval of LPS-treated animals to 35.2 hours (95% CI 21.0-49.2). LPS alone resulted in a 100% rate of stillbirth. Fifty-eight percent of fetuses were already dead 16 hours after LPS. In contrast, only 33% of fetuses were dead 16 hours after LPS (P =.001) when NAC was given. LPS was followed by a reduction in maternal (LPS: 26.3 nmol/mg [95% CI 19.9-32.8] vs CRL: 41.3 nmol/mg [95% CI 34.7-47.9, P <.01]) and fetal GSH (LPS: 19.7 nmol/mg [95% CI 11.7-27.8] vs CRL: 34.5 nmol/mg [95% CI 32.0-37.0, P <.001]). This decline was reversed by NAC (NAC/LPS maternal GSH: 37.0 nmol/mg [95% CI 22.5-51.5] and fetal GSH: 28.4 nmol/mg [95% CI 22.8-33.9]). Importantly, maternal liver GSH impacted on fetal survival. NAC/LPS mothers with living pups 16 hours after LPS had significantly higher liver GSH compared with NAC/LPS mothers whose pups died in utero. In fact, all NAC-treated mice whose hepatic GSH exceeded 20 nmol/mg had living fetuses at 16 hours.
CONCLUSION: Maternal inflammation in C57Bl/6 mice results in oxidative stress associated with maternal and fetal GSH depletion. Oxidative stress damages the fetus independent of prematurity. Restoration of maternal and fetal oxidative balance by NAC protects the fetus and reduces the rate of preterm birth.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12548218     DOI: 10.1067/mob.2003.112

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  54 in total

1.  Chronic fetal hypoxia produces selective brain injury associated with altered nitric oxide synthases.

Authors:  Yafeng Dong; Zhiyong Yu; Yan Sun; Hui Zhou; Josh Stites; Katherine Newell; Carl P Weiner
Journal:  Am J Obstet Gynecol       Date:  2011-01-26       Impact factor: 8.661

2.  Tissue-specific induction of COX-2 and prostaglandins in lipopolysaccharide-stimulated extraplacental human gestational membranes in a 2-chamber transwell culture system.

Authors:  Natalie W Thiex; Mark C Chames; Rita K Loch-Caruso
Journal:  Reprod Sci       Date:  2010-09-22       Impact factor: 3.060

3.  Inhibition of choriodecidual cytokine production and inflammatory gene expression by selective I-kappaB kinase (IKK) inhibitors.

Authors:  D De Silva; M D Mitchell; J A Keelan
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

4.  Protective effect of N-acetylcysteine on liver damage during chronic intrauterine hypoxia in fetal guinea pig.

Authors:  Kazumasa Hashimoto; Gerard Pinkas; LaShauna Evans; Hongshan Liu; Yazan Al-Hasan; Loren P Thompson
Journal:  Reprod Sci       Date:  2012-04-24       Impact factor: 3.060

5.  Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels.

Authors:  Raghavendra S Navath; Yunus E Kurtoglu; Bing Wang; Sujatha Kannan; Robert Romero; Rangaramanujam M Kannan
Journal:  Bioconjug Chem       Date:  2008-12       Impact factor: 4.774

6.  Arsenate-induced maternal glucose intolerance and neural tube defects in a mouse model.

Authors:  Denise S Hill; Bogdan J Wlodarczyk; Laura E Mitchell; Richard H Finnell
Journal:  Toxicol Appl Pharmacol       Date:  2009-05-14       Impact factor: 4.219

7.  Fetal renal artery impedance as assessed by Doppler ultrasound in pregnancies complicated by intraamniotic inflammation and preterm birth.

Authors:  Humberto Azpurua; Antonette T Dulay; Irina A Buhimschi; Mert O Bahtiyar; Edmund Funai; Sonya S Abdel-Razeq; Guoyang Luo; Vineet Bhandari; Joshua A Copel; Catalin S Buhimschi
Journal:  Am J Obstet Gynecol       Date:  2009-02       Impact factor: 8.661

8.  Involvement of reactive oxygen species in brominated diphenyl ether-47-induced inflammatory cytokine release from human extravillous trophoblasts in vitro.

Authors:  Hae-Ryung Park; Patricia W Kamau; Rita Loch-Caruso
Journal:  Toxicol Appl Pharmacol       Date:  2013-12-01       Impact factor: 4.219

Review 9.  Nitrative and oxidative stress in toxicology and disease.

Authors:  Ruth A Roberts; Debra L Laskin; Charles V Smith; Fredika M Robertson; Erin M G Allen; Jonathan A Doorn; William Slikker
Journal:  Toxicol Sci       Date:  2009-08-05       Impact factor: 4.849

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.